Navigation Links
Murray Leads Delegation in Securing $2.1 Million for Proton Therapy Center
Date:12/21/2007

Leading-edge radiation treatment facility to serve Pacific Northwest

SEATTLE, Dec. 21 /PRNewswire/ -- Steadfast support by Washington Sen. Patty Murray and the western Washington state congressional delegation has resulted in $2.1 million in federal funding designated to help development of a state-of-the-art proton-beam therapy center by the Seattle Cancer Care Alliance (SCCA). The money is included in the 2008 Omnibus Appropriations bill signed by President Bush on Thursday, Dec. 20.

"The leadership of Senator Murray and Congressman Dave Reichert for this important regional resource for cancer patients is tremendously appreciated," said Norm Hubbard, executive vice president of the Seattle Cancer Care Alliance. "These funds are vital to help with the early capitalization of the project."

"I am so proud to be able to help the Seattle Cancer Care Alliance to further their work of improving cancer medicine and saving lives," Murray said. "This project is about helping science to move forward and providing hope for the millions of patients and families who suffer with the realities of cancer."

"This funding victory will help make a promising new treatment a reality for patients fighting cancer, especially children," said Reichert. "I was pleased to work with my colleagues to secure $1.4 million for SCCA in the Health and Human Services appropriations bill, and I'm especially proud that my advocacy brought home an additional $738,000 for this important new therapy in a separate spending measure. This success is a great example of how members can work together in the best interest of their constituents."

The SCCA's Proton Beam Center is projected to open in early 2012. The center will serve patients from the six-state Pacific Northwest region of Washington, Oregon, Idaho, Alaska, Montana and Wyoming.

Proton therapy uses an external beam of precisely-targeted, high-energy protons. The primary difference between proton beam therapy and conventional radiation therapy is the ability to deliver radiation more precisely to the tumor without damaging healthy tissues. There are only five full-scale proton beam centers currently operating in the United States; the closest to Seattle is in southern California.

Proton beams are used today to treat many solid-tumor cancers such as those of the eye, skull base, head and neck, and prostate. However, the potential exists to treat many more types of tumors, including those of the lung, breast and abdomen. Researchers are particularly interested in the use of proton-beam therapy for children, who are more sensitive to the side effects of radiation than adults.

"Proton beam radiation is considered one of the major advances in radiation therapy to treat cancerous tumors," said George Laramore, M.D, Ph.D., chair of the Department of Radiation Oncology at the University of Washington.

"Proton beam radiation is a tremendous breakthrough in the care of children with cancer," said Thomas Hansen, M.D., Children's Hospital and Regional Medical Center CEO. "I applaud the efforts of Senator Murray and Congressman Reichert and the delegation for helping to deliver this state of the art treatment to the children of the Northwest."

"We are delighted to see the SCCA working to make this emerging technology available as a valuable treatment option for the physicians and cancer patients in our community," said Gregg Davidson, CEO of Skagit Valley Hospital in Mount Vernon, a charter member of the SCCA's growing network of affiliated hospitals and physicians throughout the Northwest.

About Seattle Cancer Care Alliance

Seattle Cancer Care Alliance, established in 1998, unites the adult and pediatric cancer-care services of Fred Hutchinson Cancer Research Center, UW Medicine and Children's Hospital and Regional Medical Center. A major focus of SCCA is to speed the transfer of new diagnostic and treatment techniques from the research setting to the patient bedside while providing premier, patient-focused cancer care. Patients who come to SCCA receive the latest research-based cancer therapies as well as cutting-edge treatments for a number of non-malignant diseases under development by its partner organizations. SCCA has three clinical-care sites: an outpatient clinic on the Fred Hutchinson campus, a pediatric-inpatient unit at Children's and an adult-inpatient unit at UW Medical Center. For more information about SCCA, visit http://www.seattlecca.org.

Media Contact:

Dean Forbes, (206) 667-2896; 206-605-0311

dforbes@fhcrc.org


'/>"/>
SOURCE Seattle Cancer Care Alliance
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Epeius Biotechnologies Leads With Keynote Address on the Advent of Pathotropic Medicine for Cancer at the Global Pharma R&D Summit Conference in Boston MA
2. International Substance Detection Firm IDenta To Release New Lead Test Kit - Rash Of Toy Incidents Leads Company To Enter New Marketplace
3. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
4. H2Diesel Completes 3 Million Gallon Per Year Pilot Facility
5. Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million
6. CrossFire Beilstein Database Exceeds Ten Million Compounds
7. Mirus Bio Awarded Grants & Contracts of Over $5 Million
8. Carrington Completes $8 Million Financing
9. Vermillion (Formerly Ciphergen) Announces $20.5 Million Private Placement of Common Stock
10. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
11. GenVault Partnership with Genome Quebec Brings $3.3 Million Sale of Dynamic Archive Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... HILDEN , Germany and ... QGEN ; Frankfurt Prime Standard: ... new QIAseq Targeted RNA Panels for gene expression profiling, ... next-generation sequencing (NGS). The panels enable researchers to select ... expression fold changes and discover interactions between genes, cellular ...
(Date:2/11/2016)... 2016  Spectra BioPharma Selling Solutions (Spectra) is ... biopharma companies the experience, expertise, operational delivery and ... sales teams. Created in concert with industry leading ... strategic and tactical needs of its clients by ... both personal and non-personal promotion. ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... cutting-edge information focused on the development and manufacture of biopharmaceuticals and therapeutics, ... sponsor of the 2016 BioProcess International Awards – Recognizing Excellence in the ...
(Date:2/11/2016)... DELRAY BEACH, Florida , February 11, 2016 ... --> PositiveID Corporation ("PositiveID" or "Company") (OTCQB: ... and diagnostics, announced today that its Thermomedics subsidiary, ... significant progress on its growth plan in January ... healthcare products distributors, increasing sequential monthly sales growth, ...
Breaking Biology Technology:
(Date:2/5/2016)... DUBLIN , Feb. 5, 2016 /PRNewswire/ ... the addition of the "Global Facial ... offering. --> http://www.researchandmarkets.com/research/5kvw8m/global_facial ) has ... Facial Recognition Market 2016-2020" report to ... Markets ( http://www.researchandmarkets.com/research/5kvw8m/global_facial ) has announced the ...
(Date:2/3/2016)... , Feb. 3, 2016 Vigilant Solutions ... Police Department in Missouri solved ... plate reader (LPR) data from Vigilant Solutions. ... case in which the victim was walking out of a convenience store and ... space next to his vehicle, striking his vehicle and ...
(Date:2/2/2016)... , Feb. 2, 2016 Checkpoint ... that Rising Market Are you interested in ... forecasts revenues for checkpoint inhibitors. Visiongain,s report gives ... submarket, product and national level. Avoid falling ... what progress, opportunities and revenues those emerging cancer ...
Breaking Biology News(10 mins):